Marc Ballas

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells

Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

Bronchioloalveolar Carcinoma: The Case for Two Diseases

Advances in the treatment of neurofibromatosis-associated tumours

Targeting apoptosis in cancer therapy

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Development of therapeutic antibodies for the treatment of diseases

Ramucirumab in the treatment of non-small cell lung cancer

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Repurposing approved drugs on the pathway to novel therapies

The Next Decade of Immune Checkpoint Therapy

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Cancer immunotherapy using checkpoint blockade

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy

Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.

A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).

Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors